Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 34 (1), 29-48

A New Chemotherapeutic Investigation: Piracetam Effects on Dyslexia

Affiliations

A New Chemotherapeutic Investigation: Piracetam Effects on Dyslexia

C H Chase et al. Ann Dyslexia.

Abstract

Piracetam, a new drug which is thought to enhance learning and memory consolidation, was given in a 3300 mg daily dose to half of a group of fifty-five (55) dyslexic boys aged eight to thirteen years in a twelve week, double-blind, placebo controlled study. All subjects met stringent criteria, including: normal intelligence, normal educational opportunities, no severe emotional problems, no neurological handicaps, good physical health, not taking other psychotropic medication, and scoring at least 1 1/2 years below their mental age equivalent on the Gilmore Oral Reading Test. The children's perceptual, language, and memory skills were examined and their reading, spelling, and writing abilities were measured using standardized instruments. Compared to the placebo control group, individuals treated with Piracetam showed statistically significant improvements above their baseline scores on measures of effective reading accuracy and comprehension, reading speed, and writing accuracy. The medication was extremely well tolerated, and all medical examinations showed no untoward effects. These results encourage further study of Piracetam's potential as an adjunct for the clinical remediation of dyslexia.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

References

    1. J Learn Disabil. 1980 Feb;13(2):87-97 - PubMed
    1. J Child Psychol Psychiatry. 1981 Jul;22(3):283-90 - PubMed
    1. Dev Med Child Neurol. 1975 Apr;17(2):150-63 - PubMed
    1. Can Med Assoc J. 1975 Jan 25;112(2):159-65 - PubMed
    1. Psychopharmacol Bull. 1980 Jul;16(3):65-6 - PubMed
Feedback